Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (107619)	7/14/2000 9:42:43 AM
From: Jenna	Respond to of 120523

Short TLGD, short NEWP.. just taking profits in others so far, ELNT not just yet, maybe never.

To: Jenna who wrote (107619)	7/14/2000 9:45:22 AM
From: Jenna	Read Replies (2) \| Respond to of 120523

Early morning shorts: ORCH

To: Jenna who wrote (107619)	7/14/2000 9:50:41 AM
From: Jerry Olson	Respond to of 120523

Jen check out QCOM if it takes out the hod at 64+++ gap open tacticv 64 was a triple top breakout... 63 for KLIC is a double top...

To: Jenna who wrote (107619)	7/14/2000 10:32:08 AM
From: johnsto1	Read Replies (1) \| Respond to of 120523

ORCH on sale...wsj article coming off PB Sciences and Millennium deal July 14, 2000 -------------------------------------------------------------------------------- Orchid Makes a Pact to Map Differences in Gene by Ethnicity By a WALL STREET JOURNAL Staff Reporter CHICAGO -- The SNP Consortium Ltd., an international public-private group that is mapping variations in the human genetic code, struck a deal with Orchid BioSciences to determine the frequency of certain genetic differences among several ethnic groups. Under the agreement, Orchid, Princeton, N.J., will examine about 60,000 single-letter variations in genetic code in samples from anonymous American donors who are Caucasian, African-American and Asian-American. Terms weren't disclosed. Orchid will make public the results of the analysis, which are expected in early 2001. Single nucleotide polymorphisms, or SNPs, are one-letter variations in the 3.1 billion chemical bases that make up the genetic code. Separately, the SNP Consortium said it expects to announce shortly that two major academic institutions will conduct a similar analysis of an additional 60,000 SNPs. Some SNPs are medically significant, predisposing people to disease or thwarting drug therapies used to treat them. Others account for distinctive human traits, such as hair and eye color. By constructing a map of these variations, researchers in academia and the pharmaceutical industry expect to pinpoint targets for new drugs and make better use of existing drugs. Researchers are interested in the prevalence of certain variations in different ethnic groups because these may explain disparities in the particular diseases' rates or responses to therapies. They may also help scientists target genetic variations that are important for most or all ethnic groups. The backers of the SNP Consortium members include the Wellcome Trust in the U.K., Amersham Pharmacia Biotech, AstraZeneca, Bayer Corp., Bristol-Myers Squibb Co., Hoffmann-La Roche Inc., Glaxo Wellcome Inc., Aventis Co., Novartis AG, Pfizer Inc., Pharmacia Corp. and SmithKline Beecham PLC.